Literature DB >> 748391

Effect of calcitonin treatment on osteoclast counts in Paget's disease of bone.

C P Williams, G Meachim, W H Taylor.   

Abstract

Histological and biochemical changes during calcitonin treatment have been studied in 15 patients with Paget's disease of bone. For each patient, osteoclast counts were made by the same observer on serial needle biopsies of diseased bone from the posterosuperior iliac spine. Serial estimations were also made of the serum alkaline phosphatase and urinary hydroxyproline excretion. A total of 66 biopsies was examined (ranging from two to seven per patient). Osteoclast populations and the biochemical measurements were log normally distributed. During calcitonin treatment there was a statistically significant decrease in: (1) the total osteoclast count per square millimetre; (2) the number per square millimetre of osteoclasts in resorption cavities on the trabecular surface; (3) the relative proportion of osteoclasts sited in resorption cavities compared with total osteoclasts; (4) the serum alkaline phosphatase level; (5) 24-hour urinary hydroxyproline excretion. On stopping treatment there was a statistically significant increase in all of these histological and biochemical values except that the proportion of osteoclasts in resorption cavities remained low. The trabecular cement line pattern remained abnormal during and after treatment in all biopsies examined, and complete suppression of osteoclast activity was not observed. One of the patients developed a Paget's osteosarcoma while on calcitonin therapy.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 748391      PMCID: PMC1145533          DOI: 10.1136/jcp.31.12.1212

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  12 in total

1.  ESTIMATION OF HYDROXYPROLINE BY THE AUTOANALYSER.

Authors:  R A GRANT
Journal:  J Clin Pathol       Date:  1964-11       Impact factor: 3.411

2.  STATISTICS IN THE PRACTICE OF MEDICINE.

Authors:  R G HOFFMANN
Journal:  JAMA       Date:  1963-09-14       Impact factor: 56.272

3.  Osteoclast ultrastructure in Paget's disease.

Authors:  A Rebel; K Malkani; M Baslé; C Bregeon
Journal:  Calcif Tissue Res       Date:  1976-04-20

4.  [Intermittent treatment of Paget's disease of bone with calcitonin: histological study].

Authors:  J Eisinger; A M Laponche
Journal:  Rev Rhum Mal Osteoartic       Date:  1976 Jul-Sep

5.  Ultrastructural effects of calcitonin on osteoclasts in tissue culture.

Authors:  D M Kallio; P R Garant; C Minkin
Journal:  J Ultrastruct Res       Date:  1972-05

6.  Human calcitonin in the treatment of Paget's bone disease.

Authors:  N J Woodhouse; P Bordier; M Fisher; G F Joplin; M Reiner; D N Kalu; G V Foster; I MacIntyre
Journal:  Lancet       Date:  1971-06-05       Impact factor: 79.321

7.  The ultrastructure of the osteoclast and its functional implications.

Authors:  M E Holtrop; G J King
Journal:  Clin Orthop Relat Res       Date:  1977 Mar-Apr       Impact factor: 4.176

8.  The osteoclast: review of ultrastructure, origin, and structure-function relationship.

Authors:  G Göthlin; J L Ericsson
Journal:  Clin Orthop Relat Res       Date:  1976-10       Impact factor: 4.176

9.  The clinical and metabolic effects of porcine calcitonin on Paget's disease of bone.

Authors:  F Shai; R K Baker; S Wallach
Journal:  J Clin Invest       Date:  1971-09       Impact factor: 14.808

10.  Clinical, biochemical and histological observations on the effect of porcine calcitonin in Paget's disease of bone.

Authors:  T J Martin; G Jerums; R A Melick; J M Xipell; R Arnott
Journal:  Aust N Z J Med       Date:  1977-02
View more
  2 in total

1.  Ultrastructural features of the osteoclasts from Paget's disease of bone in relation to a viral aetiology.

Authors:  L Harvey; T Gray; M N Beneton; D L Douglas; J A Kanis; R G Russell
Journal:  J Clin Pathol       Date:  1982-07       Impact factor: 3.411

2.  Paget's disease of bone. An update on management.

Authors:  D J Hosking
Journal:  Drugs       Date:  1985-08       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.